The KRAS-targeting LNPK15 showed strong antitumor efficacy in tumor xenograft mice of MIA PaCa-2 pancreatic cancer although the in vitro knock down activity of lipid-based nanoparticle was rather weak compared to its effect in tumors. Here, KRAS is linked to familial pancreatic carcinoma.